One such oral antidiabetic agent, dipeptidyl peptidase 4 (DPP-4) inhibitors, has been shown to preserve residual beta-cell function in diabetic animal models and individuals with T2D or impaired fasting glucose (IFG) [86,87,88]. Here, DPP4 is linked to type 2 diabetes mellitus.